MedTrace Logo

A Long-Term Safety Study of OZURDEX® in Clinical Practice

NCT01539577 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 875

Last updated 2016-04-20

No results posted yet for this study

Summary

This study is a multicenter, prospective, observational study to evaluate the long-term safety of OZURDEX® in patients with macular oedema following central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) or patients with non-infectious posterior segment uveitis in real-world clinical practice.

Conditions

  • Retinal Vein Occlusion
  • Macular Edema
  • Uveitis, Posterior

Interventions

DRUG

dexamethasone 700 μg intravitreal implant

dexamethasone 700 μg intravitreal implant administered according to general clinical practice.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • France
  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01539577 on ClinicalTrials.gov